Dual-agonist research
Buy tirzepatide for research, third-party tested and shipped from the US.
Tirzepatide is a synthetic 39-amino-acid peptide that engages two incretin receptors at once, and that dual design has made it one of the most sought-after compounds on the research bench. Buying it in 2026 comes with a wrinkle the semaglutide market never had: a US trade ruling reshaped where lawful material can come from. Every lot sold here ships from US stock and is matched to a published third-party certificate of analysis confirming identity and purity at ≥99% by HPLC, with heavy-metals, sterility and endotoxin results on our rotating testing cycle — so the sourcing question is settled before you ever open the vial.
by RP-HPLC
GIP + GLP-1
~4,813 Da
shipping
Where the diligence actually goes
The compound is well characterised. Provenance is the open question.
Tirzepatide itself is thoroughly documented — the mechanism, the mass, the trial record. Reading the literature is not the hard part for a research buyer.
The real work is confirming provenance and identity: where the material came from, and whether the vial holds what the label claims. This page walks through both — what the import rules changed, how the dual-agonist mechanism works, what the 2026 cardiovascular data adds, and how to verify the peptide in front of you.
On the label
Specifications
| Compound | Tirzepatide (CAS 2023788-19-2) |
|---|---|
| Also known as | GLP-2 (Tirz) |
| Size | 15 mg ($139) |
| Molecular weight | ~4,813 Da |
| Structure | 39-amino-acid dual GIP/GLP-1 agonist, C20 fatty diacid chain |
| Purity | ≥99% by HPLC, verified by Janoshik Analytical and domestic US labs |
| Quality panel | HPLC purity + MS identity on every batch; heavy metals, sterility and endotoxin on a rotating cycle |
| COA | Batch-matched, available before purchase |
| Form | Lyophilized, room-temperature stable in transit |
| Shipping | US domestic, 2 to 4 days |
How the 2026 import rules redrew sourcing
An overseas vial now carries a legal cloud and an identity risk at once.
Tirzepatide sourcing changed on April 15, 2025, when the US International Trade Commission issued a General Exclusion Order covering products that contain, or claim to contain, tirzepatide. The order is documented in the Federal Register notice, and it instructs US Customs to block infringing imports at the border. Alongside it the Commission issued Limited Exclusion Orders and Cease-and-Desist Orders against several named sellers.
The reasoning matters more than the order. Investigators found seven entities across China, Spain and three US states whose imported “tirzepatide” deceived buyers about what was in the vial — in some cases falsely claiming FDA approval, or that it contained tirzepatide at all, per Eli Lilly’s summary of the ruling. Domestic material sidesteps both problems: it stays clear of the exclusion order, and it arrives with paperwork you can check.
The dual-agonist design
What the second receptor adds
Most GLP-1 compounds speak to a single receptor. Tirzepatide speaks to two. One 39-amino-acid chain activates both the GLP-1 receptor and the GIP receptor, which is why researchers call it a dual, or “twincretin,” agonist. A C20 fatty diacid chain binds albumin and stretches its half-life to roughly five days, supporting weekly-interval study designs, and its measured mass sits near 4,813 Da — a number that becomes important when you verify identity.
The two arms do different jobs. The GLP-1 side drives glucose-dependent insulin release and the appetite signalling GLP-1 research has mapped for years. The GIP side layers on effects on insulin sensitivity and lipid handling, and the combination is what lifts tirzepatide’s measured weight change in obesity models to around 21%, against roughly 15% for single-agonist semaglutide, according to the 2026 GLP-1 pipeline review in Drug Discovery News.
For study design the takeaway is simple. Two receptors mean two pathways to account for in your controls, and a peptide whose identity has to be right on both counts — a dual agonist that turns out to be a mislabelled single agonist would break any comparison you run. An introduction to tirzepatide covers the mechanism in plain terms, our guide to GLP-1 receptor biology covers the signalling both arms share, and a primer on how semaglutide is built makes a clean single-agonist reference point.
What the 2026 cardiovascular research shows
The research file grew well beyond metabolism this year.
The SURPASS-CVOT trial, published in the New England Journal of Medicine on December 18, 2025, followed 13,299 participants and compared tirzepatide against dulaglutide over a median four years. Tirzepatide met the bar for cardiovascular noninferiority, with major adverse cardiac events at 12.2% versus 13.1%, as reported by tctmd. Lead investigator Stephen Nicholls framed the result as broadening the settings the agent can be used in, and widening patient choice.
Practice data landed in the same place. A matched-cohort study published on August 6, 2026 tracked 7,442 adults with type 2 diabetes and established cardiovascular disease, and found one-year major cardiac events at 2.9% with tirzepatide versus 4.4% with a comparator — a hazard ratio of 0.68, summarised by Healio. Lead author Nils Krüger noted the findings support viewing tirzepatide as more than glucose and weight reduction for this population.
For a research audience, the signal is scope. Tirzepatide has become a probe for cardiometabolic questions far past its original remit, which is exactly what keeps demand high for well-characterised, lab-grade material with a certificate behind it.
Confirming you have real tirzepatide
Five tests, two cadences
The import ruling and the identity question meet on a single document. After a border enforcement action built partly on fake and mislabelled product, a certificate you can read before you buy stops being a nicety.
-
01
Purity
RP-HPLC
Run on every batch. Shows how much of the vial is intact tirzepatide, flagging the truncated fragments a 39-residue synthesis can leave behind.
-
02
Identity
Mass spectrometry
Run on every batch. Confirms the measured mass against the ~4,813 Da target — the fastest way to catch a single agonist wearing a dual-agonist label.
-
03
Bacterial endotoxin
LAL assay
Run on a rotating cycle across batches. Screens for bacterial cell-wall fragments that stay active at trace levels and skew cell-based work.
-
04
Sterility
Direct inoculation
Run on a rotating cycle across batches. Confirms no viable microbial growth is present in the lot.
-
05
Heavy metals
ICP-MS
Run on a rotating cycle across batches. Quantifies lead, arsenic, cadmium and mercury, which synthesis reagents and glassware can carry into a lot.
Purity alone answers one question. Reading the panel takes a little practice, and it is where the last point between 98% and 99% stops being a rounding difference. Every batch here is tested for identity and purity by an independent lab, heavy metals, sterility and endotoxin run on a rotating cycle, and the results live in an open library you can check against your order before the vial arrives.
What a peptide COA tells you HPLC vs mass spec Browse the COA library Our testing standard
Choosing a compound
Semaglutide, tirzepatide, retatrutide
Each added receptor target lifts the ceiling. Tirzepatide sits in the middle: more reach than the single agonist, more literature than the triple.
Semaglutide
GLP-1 receptor agonist
31-aa peptide, ~4,113 Da
The single-agonist reference, and the deepest literature of the three. Around 15% measured weight change in obesity models.
Tirzepatide
Dual GIP + GLP-1 agonist
39-aa peptide, ~4,813 Da
The dual-agonist benchmark. The GIP arm lifts measured weight change to around 21%, and the C20 diacid gives it a half-life near five days.
Retatrutide
Triple GIP + GLP-1 + glucagon
39-aa peptide, ~4,867 Da
Adds the glucagon arm and its energy-expenditure effect, reaching around 30% in trials. The usual next step when a dual agonist is not enough.
Keeping a comparison series on one source keeps your variables clean. All three ship with the same testing standard and the same batch-matched certificate, so the only thing changing between arms is the compound.
Handling and storage
Three steps, and the order matters.
-
1
Store cold, dry and dark
Lyophilized tirzepatide ships stable at room temperature and keeps best in long-term storage at −20°C, dry and away from light.
-
2
Reconstitute with a slow roll
Add bacteriostatic water and swirl the vial gently. A 39-residue peptide takes mechanical stress poorly.
-
3
Portion into aliquots
Split the solution into single-use volumes so no vial goes through the repeated freeze-thaw cycles that erode integrity.
Anyone newer to bench handling will find the logic behind these steps in our introduction to peptides.
Before you order
Frequently asked questions
Is tirzepatide legal to buy for research?
Yes, when it is sold and bought strictly as a research-use-only material for laboratory work, with no human or veterinary use. The research framing is the line that keeps it lawful, and it should appear clearly on the product, the COA, and your own records.
What about the tirzepatide import ban?
In April 2025 the US ITC issued a General Exclusion Order blocking imports of tirzepatide and look-alike products that infringe or misrepresent their contents. For a research buyer the practical takeaway is simple: know exactly what you are buying, from a supplier that publishes a batch-matched, third-party COA you can read before you order.
Can I see the COA before ordering?
Yes. Each batch is matched to a certificate available before purchase, so you can verify identity and purity and see which rotating-cycle results apply to that lot before you order. The batch number and test date are printed on the certificate itself.
What makes tirzepatide a dual agonist?
A single 39-amino-acid chain activates both the GLP-1 and GIP receptors at once. That two-receptor design, sometimes called a twincretin, is what separates tirzepatide from single-target GLP-1 compounds and drives its stronger effect in metabolic models.
How is tirzepatide different from semaglutide for research?
Semaglutide acts on the GLP-1 receptor alone and serves as the field’s single-agonist reference. Tirzepatide adds GIP receptor activity, which lifts its measured weight change in obesity models to around 21% versus roughly 15%, making the two a natural comparison pair.
Is there a peptide stronger than tirzepatide?
Retatrutide, a triple agonist that adds glucagon receptor activity to the GIP and GLP-1 arms, reaches higher measured weight change in models and sits at the leading edge of incretin research. It is the usual next step when a protocol needs more than a dual agonist delivers.
What is tirzepatide’s molecular weight and structure?
It is a 39-amino-acid dual GIP/GLP-1 agonist with a molecular weight near 4,813 Da and a C20 fatty diacid chain that extends its half-life to about five days.
How should I store and reconstitute it?
Store the dry powder at −20°C, shielded from light and moisture. When you reconstitute, add bacteriostatic water and mix with a slow swirl, then split the solution into single-use aliquots so no vial goes through repeated freeze-thaw cycles. Our guides on peptide storage and peptide reconstitution cover both in detail.
Why does third-party testing matter for tirzepatide specifically?
A 39-residue dual agonist has more room for synthesis errors than a shorter peptide, and the import market has been flagged for mislabelled product. Independent HPLC and mass spec confirm both purity and the exact identity before the material reaches your bench.
Are these peptides approved for human use?
No. GLP-2 (Tirz) sold here is a research-use-only material, not an approved drug or supplement, and is not intended for human or veterinary use.
Sourcing tirzepatide with confidence
What changed this year is the sourcing map, not the science.
Tirzepatide earned its standing as the dual-agonist benchmark, and 2026 has only deepened its research file — from the SURPASS-CVOT cardiovascular data to an everyday clinical record that reads the same way.
With the ITC exclusion order on imported and misrepresented products, US-made material with a certificate you can verify is the straightforward choice. Provenance you can prove, identity you can check, and a compound whose science keeps expanding.
Research-grade peptides
99%+ purity. Verified every batch.
Identity and purity verified on every batch by third-party domestic labs and Janoshik Analytical. Shipped same day from California.
